Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions
13.2.2025 10:00:00 CET | Business Wire | Press release
Ricardo has signed a multi-year deal to supply transmissions for Porsche 911s reimagined by Singer
Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK.
The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911.
Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science.
Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission able to accommodate the additional demands that a turbocharged car places on the drivetrain. Designed to seamlessly integrate into the existing chassis, the transmission will enable smooth, engaging gear shift operations despite the increased torque and power demands.
The transmissions will be manufactured and tested at Ricardo’s state of the art Midlands Technical Centre in Leamington Spa, UK.
Richard Guest, Managing Director of Performance Products at Ricardo, said: “We are delighted to be working on this significant multi-year project, supplying Singer in the UK and US with a series of transmissions that will support the growth of their customer base. The passion and detail that they demonstrate through these vehicles is a great match with the drivetrain expertise that Ricardo can provide. We look forward to supporting the Singer team on this project and building on our existing relationship.”
Mazen Fawaz, Chief Strategy Officer, Singer Group, notes: “Our approach is always based around execution without compromise. This leads us to seek out and collaborate with the best in the world. An exceptional, truly engaging, manual transmission is an essential part of the remarkable sports cars that we pursue, on behalf of some of the most discerning drivers in the world. We look forward to continuing this pursuit in collaboration with Ricardo.”
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering innovative cross-sector sustainable outcomes to support energy transition, environmental services together with safe and smart transport. Our global team of consultants, environmental specialists, engineers and scientists support our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
About Singer
Founded in California in 2009, Singer represents a philosophy simply expressed as A Relentless Pursuit of Excellence.
The company has become renowned for its collaboration with owners of the air-cooled Porsche 911 to reimagine bespoke restorations. Singer’s philosophy embodies:
- A highly personalized approach and exquisite execution
- A passionate focus on iconic design and a homage to the world’s most iconic sportscars.
- Modern engineering and material science combined with jewel-like details.
- A deep connection with California and its automotive zeitgeist.
Visit www.singervehicledesign.com
Singer is not sponsored, associated, approved, endorsed nor, in any way, affiliated with Porsche Cars North America, Inc., or Dr. Ing. h.c. F. Porsche, AG. Dr. Ing. h.c. F. Porsche AG is the owner of numerous trademarks, both registered and unregistered, including, without limitation, the Porsche Crest®, Porsche®, and the model numbers and names and the distinctive shapes of the Porsche automobiles, such as the federally registered 911 automobile. Any mention of Porsche Cars North America, Inc., or Dr. Ing. h.c. F. Porsche, AG. trademarked names or other marks is for purpose of reference only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212195492/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom